Long description:

Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal presents in-depth content written by international experts in the study of resistance to anti-CD20 antibodies and approaches for their reversal. Anti-CD20 antibodies are used to achieve B cell depletion and are developed to treat B cell proliferative disorders, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In the past two decades, anti-CD20 antibodies have revolutionized the treatment of all B cell malignancies, however, there are patients that fail to respond to initial therapy or relapse sooner. This book explores new and existing avenues surrounding Anti-CD20 antibodies.

In recent years, several next-generation anti-CD20 therapies have been developed but predicting and reversing resistance is still a challenging task. These areas are being actively studied as they represent a potential to improve anti-CD20 therapies and are discussed thoroughly in the book.

It is a valuable resource for researchers, students and member of the biomedical and medical fields who want to learn more about resistance to anti-CD20 antibodies and their reversal.

Table of Contents:

1. Therapeutic antibodies against cancer - A step toward the treatment
2. Anti-CD20 antibody treatment for B-cell malignancies
3. Anti-CD20 antibody treatment for diffuse large B cell lymphoma: Genetic alterations and signaling pathways
4. Non-Hodgkin’s lymphoma treated with anti-CD20 antibody-based immunochemotherapy
5. Targeted therapies for follicular lymphoma
6. Treatment of relapsed follicular lymphoma
7. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia
8. Clinical relevance and therapeutic implications of CD20 expression in Hodgkin's lymphoma
9. Therapeutic options for rituximab-resistant patients
10. Mechanisms of resistance to anti-CD20 antibodies in lymphoid malignancies
11. Kinetic exclusion assay using cellular membranes for affinity determination of anti-CD20 antibody
12. Clinical efficacy of anti-CD20 antibodies in autoimmune diseases
13. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis
14. Anti-CD20 antibodies in glomerular disease, their resistance and reversal approaches
15. Adverse events following rituximab therapy in pemphigus patients
16. Immune monitoring of patients treated with anti-CD20 therapeutic monoclonals for autoimmune disorders
17. Clinical efficacy of anti-CD20 antibodies in neurological and neuromuscular diseases
18. Highlights and perspectives by the contributors of the volume (resistance to anti-CD20 antibodies and approaches for their reversals)